戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 uction cycle 1, 183 after cycle 2, 124 after consolidation therapy).
2 o receive G-CSF through 2 monthly courses of consolidation therapy.
3 dose treatment versus conventional doses for consolidation therapy.
4 ieved by increased anthracycline dose during consolidation therapy.
5 200 mg/day for 14 days, followed by standard consolidation therapy.
6 ristine, actinomycin D, and cyclophosphamide consolidation therapy.
7 tance genes after completion of induction or consolidation therapy.
8 microbiota after completion of induction and consolidation therapy.
9 es of 250 mg/m(2), and was continued through consolidation therapy.
10 o assess HRQOL at end of induction and after consolidation therapy.
11 spectively, in 141 and 102 HR patients after consolidation therapy.
12  received up to four cycles of pemetrexed as consolidation therapy.
13 ve, and 26 remain progression free after ICE consolidation therapy.
14  and were eligible to receive their assigned consolidation therapy.
15 ICE (ifosfamide, carboplatin, and etoposide) consolidation therapy.
16 se of HDAC followed by alternative intensive consolidation therapy.
17 cal trials and were assigned to receive HDAC consolidation therapy.
18 trexate [HDMTX]; 2.5 or 5.0 g/m2 per day) as consolidation therapy.
19 ctive initial therapy and further studies of consolidation therapy.
20 e alone followed 2 months later by rituximab consolidation therapy.
21 -alpha transcript by the completion of their consolidation therapy.
22 omide, and dexamethasone (VRD) induction and consolidation therapies.
23 ease, as determined by flow cytometry, after consolidation therapy (100% positive predictive value).
24 logeneic transplantation compared with other consolidation therapies (5-year OS, 54.7% v 0%; Mantel-B
25 mide, and dexamethasone (Isa-KRd) to receive consolidation therapy according to their MRD status.
26 ction therapy followed by transplant without consolidation therapy, adding Isa to RVd resulted in a s
27  and ASCT are both feasible and effective as consolidation therapies after high-dose methotrexate-bas
28 urrent data fail to support a clear role for consolidation therapy after chemoradiotherapy; however,
29 nd studies investigating the role of SIRT as consolidation therapy after chemotherapy are needed.
30 , in the CONSOLIDATE trial ((177)Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with S
31 ion was retained despite readministration as consolidation therapy after double autologous transplant
32 phalan plus stem-cell transplantation or MPR consolidation therapy after induction, and 251 patients
33                             Interferon alpha consolidation therapy after intensive treatment with ant
34 ore autologous HSCT and two 28-day cycles of consolidation therapy after.
35 1 years for patients who received interferon consolidation therapy and 3.2 years for patients who wer
36 e therapy (D-VRd group) or VRd induction and consolidation therapy and lenalidomide maintenance thera
37 ogression received an additional 3 months of consolidation therapy and then 4 months of maintenance t
38 ubcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance th
39 mission could be treated with five cycles of consolidation therapy and up to 12 months of maintenance
40  daratumumab combined with VRd induction and consolidation therapy and with lenalidomide maintenance
41                 Thirty-two patients received consolidation therapy, and 18 received additional ATO as
42  new regimens for induction of remission and consolidation therapy, and bone-marrow transplantation h
43 solidation therapy, standard-dose cytarabine consolidation therapy, and high-dose cytarabine consolid
44 l transplantation, as well as into post-ASCT consolidation therapy, and in the maintenance setting.
45                                           If consolidation therapies are to be determined by relapse
46 te remission (CR) were treated with HD Ara-C consolidation therapy as a method of in vivo purging bef
47 solidation therapy, and high-dose cytarabine consolidation therapy before HLA-identical sibling trans
48 ene groups after completion of induction and consolidation therapy between participants who had recei
49                                              Consolidation therapy comprised two or three additional
50 tients who had a complete remission received consolidation therapy consisting of one cycle of treatme
51                                Bone-targeted consolidation therapy consisting of one dose of Sr-89 pl
52 severe gastrointestinal (GI) toxicity during consolidation therapy containing mercaptopurine, and rem
53 er chemohormonal treatment, (177)Lu-PSMA-617 consolidation therapy demonstrated promising efficacy an
54 r placebo; those who were in remission after consolidation therapy entered a maintenance phase in whi
55 rity of the patients who underwent high-dose consolidation therapy experienced relapse and died with
56 ncreasing evidence that the use of high-dose consolidation therapy followed by autologous hematopoiet
57 as attained the patients received 2 weeks of consolidation therapy followed by continuation therapy.
58 , we evaluated blinatumomab as induction and consolidation therapy followed by prednisone, vincristin
59  cell transplantation (allo-HCT), or both as consolidation therapy, followed by continuation of singl
60 f children undergoing remission induction or consolidation therapy for acute lymphoblastic leukemia,
61 creased cumulative dose of idarubicin during consolidation therapy for adult AML resulted in improved
62 olerated by patients receiving induction and consolidation therapy for AML; however, there was no eff
63 ansplantation (ASCT) is the standard of care consolidation therapy for eligible patients with myeloma
64 sequent lenalidomide maintenance is standard consolidation therapy for multiple myeloma, and a subset
65 urrent data support the use of AHCT as early consolidation therapy for PTCL patients who are chemosen
66                                       HDT as consolidation therapy for relapsed ESFT seems to be asso
67  to evaluate the role of (177)Lu-PSMA-617 as consolidation therapy for residual disease after chemoho
68 he growing utilization of immunotherapy as a consolidation therapy for stage III NSCLC.
69 lloHSCT may provide a more effective type of consolidation therapy for the reduction of relapse and t
70 domide, and dexamethasone (KTd) as induction/consolidation therapy for transplant-eligible patients w
71 mab is also being studied in CLL patients as consolidation therapy for treatment of minimal residual
72 icin 12 mg/m(2) on days 1 and 3, followed by consolidation therapy (four ATRA-ATO cycles).
73 en randomized trial to compare bortezomib as consolidation therapy given after high-dose therapy and
74 rapy predicted longer PFS, regardless of the consolidation therapy given.
75                              For the latter, consolidation therapy >64 weeks reduced the relapse rate
76                                              Consolidation therapy >64 weeks seems more appropriate f
77 affected by the duration of on-therapy VR or consolidation therapy (>6 months in all studies).
78 py, lymphodepletion, and, for some patients, consolidation therapy have an important role in the succ
79  (IFM) decided to evaluate RVD induction and consolidation therapies in a sequential intensive strate
80  the efficacy of a single cycle of ATO-based consolidation therapy in a treatment regimen designed to
81  has been used for more than four decades as consolidation therapy in acute myelogenous leukemia (AML
82  in combination with intensive induction and consolidation therapy in NPM1-mutated AML.
83 fore investigated the value of bone-targeted consolidation therapy in selected patients with advanced
84 nti-NKG2A monoclonal antibody monalizumab as consolidation therapy in this setting.
85  as induction therapy, followed by intensive consolidation therapy, in inducing complete remission to
86 ogamicin (GO anti-CD33 monoclonal antibody); consolidation therapy included three additional courses
87 S for the subset of 23 patients who received consolidation therapy is 24%.
88                          In many series, the consolidation therapy is applied only to patients who ha
89 her-dose methotrexate (> or = 1 g/m2) during consolidation therapy may be useful in the treatment of
90                   IP therapy was provided as consolidation therapy (n = 89), or for treatment of pers
91 ion of adding alpha1-antagonists to the post-consolidation therapy of NB to more efficiently control
92   Responding patients received decitabine as consolidation therapy on a 5-day schedule for up to 24 c
93 ths later by 4 weekly doses of rituximab for consolidation therapy or sequential fludarabine alone fo
94 ATRA plus arsenic trioxide for induction and consolidation therapy or standard ATRA-idarubicin induct
95 ple was available for analysis at the end of consolidation therapy, overall survival at 3 years was 4
96 action between maintenance and induction and consolidation therapy (p<0.0001).
97 ual disease (MRD) at the end of induction or consolidation therapy predicts poor outcome because chil
98 on therapy after chemoradiotherapy; however, consolidation therapy remains an option for patients who
99 to 5) occurring >or= 180 days after start of consolidation therapy reported for each patient.
100                            After 3 cycles of consolidation therapy, residual disease was found in onl
101 g/m2 to CEM followed by autologous HSCT as a consolidation therapy resulted in 16% toxic mortality in
102  were randomly assigned to (90)Y-ibritumomab consolidation therapy (rituximab 250 mg/m(2) days -7 and
103                                              Consolidation therapy seemed to be beneficial for patien
104                                          VTD consolidation therapy significantly contributed to impro
105 O(3) consolidation to standard induction and consolidation therapy significantly improves event-free
106 f patients with AML in first CR receiving no consolidation therapy, standard-dose cytarabine consolid
107 e identified within 4 months after induction-consolidation therapy, suggesting that this time frame m
108                                    Intensive consolidation therapy that included autologous periphera
109                          After induction and consolidation therapy, the overall response rate was 86%
110 R-mismatched NK cells in a phase II trial as consolidation therapy to decrease relapse without increa
111                 Administering maintenance or consolidation therapy to patients with advanced NSCLC to
112 ompletion of induction, transplantation, and consolidation therapy was 58%, 70%, and 87%, respectivel
113                      The response rate after consolidation therapy was 75% (94% for weekly chemothera
114                                              Consolidation therapy was carboplatin (area under the cu
115                  Extended post-ASCT Dara-VRd consolidation therapy was highly deliverable, with limit
116                             In all patients, consolidation therapy was intended.
117 of CR patients who did not go on to protocol consolidation therapy was more than twice as high after
118 fication (DI) phase after standard induction/consolidation therapy was previously shown to improve ou
119                                         Both consolidation therapies were well tolerated.
120 ll in complete remission after two cycles of consolidation therapy were then randomly assigned to mai
121 ives of this prospective randomized study of consolidation therapy were to evaluate recurrence-free s
122 l transplantation, patients proceeded to KTd consolidation therapy, where the target doses of carfilz
123 poietic cell transplantation (AHCT) as early consolidation therapy will be the focus of this review.
124 s induction therapy for 2 weeks, followed by consolidation therapy with 200 mg/day for 8 weeks.
125 s induction therapy for 2 weeks, followed by consolidation therapy with 200 mg/day for an additional
126 nduction therapy followed by three cycles of consolidation therapy with ATRA plus chemotherapy and ma
127                                              Consolidation therapy with autologous tumor lysate-pulse
128                                              Consolidation therapy with bevacizumab and erlotinib was
129    Neoadjuvant therapy before cystectomy and consolidation therapy with biological agents after first
130 et recovery could receive up to tw cycles of consolidation therapy with CPX-351 (65 units/m(2) 90-min
131 sion rates and can bridge to more definitive consolidation therapy with curative intent.
132 e randomly assigned to receive two cycles of consolidation therapy with cytarabine 100 mg/m(2) daily
133 topenia and thrombocytopenia after intensive consolidation therapy with diaziquone (AZO) and mitroxan
134 ded four- or five-agent remission induction; consolidation therapy with doxorubicin, vincristine, cor
135 on therapy with three cycles of RVD and then consolidation therapy with either five additional cycles
136                                              Consolidation therapy with erlotinib (150 mg daily) and
137                                     Although consolidation therapy with fluconazole is associated wit
138 le (800 mg per day) for 14 days, followed by consolidation therapy with fluconazole.
139                    Rapid responders received consolidation therapy with guidelines to reduce the risk
140 therapy with daunorubicin and cytarabine and consolidation therapy with high-dose cytarabine) plus ei
141                                              Consolidation therapy with high-dose melphalan plus stem
142 sponse to initial therapy, they proceeded to consolidation therapy with melphalan, etoposide, TBI, an
143 ethotrexate-containing regimens, followed by consolidation therapy with myeloablative chemotherapy an
144 ileukemic activity of standard induction and consolidation therapy with or without the addition of th
145                                              Consolidation therapy with oregovomab did not significan
146                                              Consolidation therapy with paclitaxel and carboplatin in
147 usion, combination of standard induction and consolidation therapy with sorafenib in the schedule inv
148 , and daunorubicin, followed by 2 courses of consolidation therapy with tretinoin plus daunorubicin,
149 venetoclax (GIVe) for cycles 1 through 6 and consolidation therapy with venetoclax and ibrutinib for
150                      The hypothesis was that consolidation therapy would prolong progression-free sur

 
Page Top